Bilsen Johan, Norup Michael, Deliens Luc, Miccinesi Guido, van der Wal Gerrit, Löfmark Rurik, Faisst Karin, van der Heide Agnes
End-of-Life Care Research Group, Vrije Universiteit Brussel, Brussels, Belgium.
J Pain Symptom Manage. 2006 Feb;31(2):111-21. doi: 10.1016/j.jpainsymman.2005.07.005.
We investigated the drugs used in the alleviation of pain and symptoms (APS) with a possible life-shortening side effect in six European countries' end-of-life care. We sent mail questionnaires to physicians who signed a representative sample of death certificates in each country. APS with a possible life-shortening effect occurred from 19% of all deaths in Italy to 26% in Denmark. Physicians usually administered opioids (from 76% of APS cases in Italy to 96% in The Netherlands), but the type of opioids and administration practice differed markedly between countries. The doses of opioids given in the last 24 hours also varied significantly and were usually lower than 300 mg oral morphine equivalent (from 83% of cases in Belgium to 93% in Sweden). The highly variable results bring into question whether existing guidelines for pain relief were applied appropriately and to what extent unfounded concerns about the possible life-shortening effect of opioids resulted in less than optimal symptom management in end-of-life care.
我们调查了在六个欧洲国家临终关怀中用于缓解疼痛和症状(APS)但可能有缩短生命副作用的药物。我们向在每个国家签署具有代表性死亡证明样本的医生发送了邮寄问卷。具有可能缩短生命作用的APS在意大利占所有死亡病例的19%,在丹麦占26%。医生通常使用阿片类药物(从意大利APS病例的76%到荷兰的96%),但各国阿片类药物的类型和给药方式差异显著。过去24小时内给予的阿片类药物剂量也有很大差异,通常低于300毫克口服吗啡当量(从比利时病例的83%到瑞典的93%)。这些高度可变的结果使人质疑现有的疼痛缓解指南是否得到了适当应用,以及对阿片类药物可能缩短生命作用的无端担忧在多大程度上导致了临终关怀中症状管理未达最佳状态。